Amanda Clinic2 Min

Healthcare Professionals

Treat the signs of ageing with fast and long-lasting results.

Sinclair, has been committed to skin expertise since 1971, and more recently to the development of a safe, minimally invasive and effective portfolio of aesthetic treatments including ELLANSÉ.

Sinclair College

Sinclair College offers Sinclair partner physicians; online educational courses, training programmes, and webinars. Discover all that Sinclair College has to offer by registering today.

Register now
290A5517 RT Min

A novel approach to the art of injecting.

All you need to know to master Ellansé.

Learn more
Pagefolding 3.1 Min

Get started with ELLANSÉ

Looking to integrate ELLANSÉ into your treatment offering? Look no further, contact our team today.
I am interested in

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

Important Safety Considerations:

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.

Other potential adverse events include

- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.

- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.

- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.

- Adverse events, other than mentioned above, could occur as can be with any medical intervention.

All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Corporate Safety Group: quality@sinclair.com

For a full list of contraindications, warnings, and precautions for this product please visit http://www.sinclairpharma.com/eifu/ for a copy of the Product Instructions for Use.